HighTower Advisors’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$165K Sell
57,302
-542
-0.9% -$1.38K ﹤0.01% 3579
2026
Q1
$113K Buy
57,844
+1,715
+3% +$4.02K ﹤0.01% 3615
2025
Q4
$152K Buy
56,129
+141
+0.3% +$463 ﹤0.01% 3440
2025
Q3
$237K Buy
55,988
+4,100
+8% +$18K ﹤0.01% 3224
2025
Q2
$258K Buy
51,888
+2,355
+5% +$10.2K ﹤0.01% 3061
2025
Q1
$218K Sell
49,533
-600
-1% -$2.82K ﹤0.01% 3113
2024
Q4
$233K Sell
50,133
-192
-0.4% -$1.05K ﹤0.01% 3085
2024
Q3
$348K Sell
50,325
-80,440
-62% -$631K ﹤0.01% 2703
2024
Q2
$1.02M Buy
130,765
+46,330
+55% +$343K ﹤0.01% 1846
2024
Q1
$600K Buy
+84,435
New +$559K ﹤0.01% 2147
2022
Q1
Sell
-9,138
Closed -$300K 3508
2021
Q4
$300K Sell
9,138
-2,410
-21% -$97K ﹤0.01% 2473
2021
Q3
$474K Sell
11,548
-32,068
-74% -$1.16M ﹤0.01% 2084
2021
Q2
$1.58M Sell
43,616
-24,773
-36% -$914K ﹤0.01% 1370
2021
Q1
$2.67M Buy
68,389
+58,763
+610% +$2.64M 0.01% 991
2020
Q4
$386K Buy
+9,626
New +$442K ﹤0.01% 1770

Other funds holding GDRX

HighTower Advisors's GDRX Position: Q2 2026 in Review

HighTower Advisors reduced its GoodRx Holdings (GDRX) stake by 0.94% in Q2 2026, selling an estimated $1.38K and leaving 57,302 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3579.

HighTower Advisors first reported a position in GDRX in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.67M in Q1 2021. 162 funds tracked by Wall St. Rank hold GDRX as of Q2 2026.

  • HighTower Advisors held 57,302 shares of GoodRx Holdings worth $165K as of Q2 2026.
  • HighTower Advisors sold 542 GoodRx Holdings shares in Q2 2026, an estimated $1.38K.
  • GoodRx Holdings made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3579 holding.
  • HighTower Advisors first reported a position in GoodRx Holdings in Q4 2020 and has held it in 15 quarters since.
  • HighTower Advisors's GoodRx Holdings position peaked at $2.67M in Q1 2021.
  • 162 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.